Insider share selling, particularly below current price, is seen as negative, implying a lower price is reasonable. Modest insider ownership indicates alignment with common shareholders. The absence of insider transactions in the past three months is not encouraging.
Insiders' sales of Ryerson Holding Corporation stock raise alarms as absence of purchases is worrisome. The investor sentiment remains cautious without major insider acquisitions.
Ryerson (NYSE: RYI) is a leading value-added processor and distributor of industrial metals with operations in the United States. RYI's revenue growth from 2014 to 2022 was driven by changes in selling price rather than tonnage growth. The price growth, especially the price spike in the past 2 years, enabled it to generate strong earnings. But there were improvements in operating efficiencies and the company is financially sound. It is a cycli...
Gainers: •$ベル(VERU.US)$+25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization) •$デスクトップ メタル A(DM.US)$+15.8% (prices offering of $100 mln of 6.0% convertible se...
19
1
6
報告
我只想赚个买菜钱 :
NIO Pre-market UP 3.3%, before open market, immediately turned into RED. Only NIO able to do so. Haha.
ライアーソン ホールディングに関するコメント
BRING EM ALL WITH YOU
$スチール ダイナミクス(STLD.US)$
$ユナイテッド ステーツ スチール(X.US)$
$テルニウム(TX.US)$
$ゲルダウ(GGB.US)$
$コンパニア・シデルルジカ・ナシオナル(SID.US)$
$ラディウス リサイクリング(RDUS.US)$
$コマーシャル メタルズ(CMC.US)$
$テナリス(TS.US)$
$ライアーソン ホールディング(RYI.US)$
$ニューコア(NUE.US)$
RYI's revenue growth from 2014 to 2022 was driven by changes in selling price rather than tonnage growth. The price growth, especially the price spike in the past 2 years, enabled it to generate strong earnings. But there were improvements in operating efficiencies and the company is financially sound.
It is a cycli...
• $ベル(VERU.US)$ +25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization)
• $デスクトップ メタル A(DM.US)$ +15.8% (prices offering of $100 mln of 6.0% convertible se...
まだコメントはありません